1. Lenalidomide Induces Responses in Patients with MDS-DEL(5)Q Alone, or with One Additional Abnormality, Irrespective of Who Classification and Prognostic Categorization. (April 2017) Authors: Symeonidis, A.; Kouraklis-Symeonidis, A.; Galanopoulos, A.; Hatzimichael, E.; Zikos, P.; Vassilakopoulos, T.; Pappa, V.; Kotsianidis, I.; Dimou, M.; Palla, K.; Viniou, N.A.; Kartasis, Z.; Pontikoglou, C.; Barbarousi, D.; Pagoni, M.; Xanthopoulidis, G.; Kotsopoulou, M.; Michali, E.; Katodritou, E.... Journal: Leukemia research Issue: Volume 55(2017)Supplement 1 Page Start: S76 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. P1229: RITUXIMAB-DOSE-ADJUSTED EPOCH (R-DA-EPOCH) IN PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA (PMLBCL): REAL-LIFE EXPERIENCE ON 225 PATIENTS FROM 4 COUNTRIES. (23rd June 2022) Authors: Vassilakopoulos, T.; Ferhanoglu, B.; Horowitz, N. A.; Apostolidis, J.; Mellios, Z.; Kaynar, L.; Zektser, M.; Symeonidis, A.; Piperidou, A.; Kalpadaki, C.; Akay, O. M.; Atalar, S. C.; Sayyed, A.; Katodritou, E.; Leonidopoulou, T.; Papageorgiou, S.; Tadmor, T.; Gutwein, O.; Karakatsanis, S.; Ganzel... Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 1114 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. P1230: PET/CT IMAGING FOR RESPONSE ASSESSMENT AND TREATMENT GUIDANCE AFTER RITUXIMAB-DOSE-ADJUSTED-EPOCH(R-DA-EPOCH) IN PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA (PMLBCL):THE GREEK EXPERIENCE ON 107 PATIENTS. (23rd June 2022) Authors: Vassilakopoulos, T.; Piperidou, A.; Mellios, Z.; Verigou, E.; Kalpadakis, C.; Katodritou, E.; Papageorgiou, S.; Chatzidimitriou, C.; Giatra, C.; Leonidopoulou, T.; Xanthopoulos, V.; Karakatsanis, S.; Gainaru, G.; Vrakidou, E.; Koumarianou, A.; Hatzimichael, E.; Verrou, E.; Tsirogianni, M.; Dranda... Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 1115 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. P916: COEXISTENCE OF ≥2 HIGH-RISK MOLECULAR ABNORMALITIES SUPERVENES THE PROGNOSTIC VALUE OF THE REVISED INTERNATIONAL STAGING SYSTEM FOR MYELOMA: REAL-WORLD DATA ANALYSIS FROM THE GREEK MYELOMA STUDY GROUP. (23rd June 2022) Authors: Katodritou, E.; Dalampira, D.; Triantafyllou, T.; Gavriatopoulou, M.; Delimpasi, S.; Pouli, A.; Papadopoulou, T.; Verrou, E.; Sevastoudi, A.; Tsirou, K.; Katsika, L.; Douganiotis, G.; Karampatzakis, N.; Metallinou, T.-E.; Palaska, V.; Kotsopoulou, M.; Lalayianni, C.; Kyrtsonis, M.-C.; Spanoudakis... Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 806 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. PROGNOSTIC FACTORS (PFs) IN PRIMARY MEDIASTINAL LARGE B‐CELL LYMPHOMA (PMLBCL) TREATED WITH RITUXIMAB‐CHOP (RCHOP) ± RADIOTHERAPY (RT). (12th June 2019) Authors: Vassilakopoulos, T.P.; Papageorgiou, S.G.; Michail, M.; Angelopoulou, M.K.; Kourti, G.; Kalpadakis, C.; Kotsopoulou, M.; Leonidopoulou, T.; Konstantinidou, P.; Kotsianidis, I.; Boutsis, D.; Michali, E.; Sachanas, S.; Terpos, E.; Karianakis, G.; Poziopoulos, C.; Vadikolia, C.; Pigaditou, A.; Vraki... Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 266 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗